# Trends in clinical development for PD-1/PD-L1 inhibitors

Jia Xin Yu, Jeffrey P. Hodge, Cristina Oliva, Svetoslav T. Neftelinov, Vanessa M. Hubbard-Lucey and Jun Tang

1,103 active trials testing 159 targets in 2017

2,251 active trials testing 295 targets in 2019

Supplementary Figure 1. Target landscapes of combination trials in 2019 and 2017. The number of combination trials has doubled in the past 2 years, with an increase of 136 additional combination targets.

Supplementary Figure 2. Average planned patient enrollment goes down since 2014. *Only data from the first 3 quarters of 2019 was used to generate the analysis in the chart above.

Supplementary Figure 3. The evolution of new trials started per year by different cancer types. Cancer types with approved PD-1/L1 mabs have shown either slow growth or decrease of new trials per year.

Methods: The clinical trial information was collected in September 2019 from clinicaltrials.gov. The classification of combination trial type and the identification of combination targets was based on CRI IO Analytics. The actual clinical trial recruitment information was collected from IQVIA internal database that tracks the real-time status of clinical trials managed by IQVIA. This patient recruitment analysis included information from 629 unique clinical trial sites from 55 clinical trials. These data only reflect a small fraction of 2,975 active PD-1/L1 clinical trials, and the results are therefore limited in reflecting the real actual patient recruitment rate of all ongoing PD-1/L1 trials.